Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SU14813 |
Synonyms | |
Therapy Description |
SU14813 is a multi-kinase inhibitor with activity against VEGFR1-3, PDGFRA, PDGFRB, KIT, and FLT3, which potentially results in decreased tumor angiogenesis and growth (PMID: 16891463, PMID: 20605934). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SU14813 | FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 32 | SU14813 is a multi-kinase inhibitor with activity against VEGFR1-3, PDGFRA, PDGFRB, KIT, and FLT3, which potentially results in decreased tumor angiogenesis and growth (PMID: 16891463, PMID: 20605934). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | SU14813 | Phase I | Actionable | In a Phase I trial, SU14813 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with an objective response rate of 20% (13/65), including 1 complete response and 12 partial responses (PMID: 20605934). | 20605934 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|